Intest Res.  2017 Apr;15(2):244-248. 10.5217/ir.2017.15.2.244.

Fecal microbiota transplantation for refractory Crohn's disease

Affiliations
  • 1Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. yscho@catholic.ac.kr
  • 2Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.

Abstract

Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.

Keyword

Crohn disease; Fecal microbiota transplantation; Dysbiosis; Biologic therapy

MeSH Terms

Biological Therapy
Colitis
Crohn Disease*
Dysbiosis
Fecal Microbiota Transplantation*
Gastrointestinal Microbiome
Humans
Immune System
Inflammation
Inflammatory Bowel Diseases
Lymphoma
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error